SG11201807960PA - Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer - Google Patents
Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancerInfo
- Publication number
- SG11201807960PA SG11201807960PA SG11201807960PA SG11201807960PA SG11201807960PA SG 11201807960P A SG11201807960P A SG 11201807960PA SG 11201807960P A SG11201807960P A SG 11201807960PA SG 11201807960P A SG11201807960P A SG 11201807960PA SG 11201807960P A SG11201807960P A SG 11201807960PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- paris
- particles
- treating cancer
- pct
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 125000004122 cyclic group Chemical group 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229920001817 Agar Polymers 0.000 abstract 1
- 241001028048 Nicola Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000004575 stone Substances 0.000 abstract 1
- 239000010902 straw Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2016/055738 WO2017157437A1 (en) | 2016-03-16 | 2016-03-16 | Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807960PA true SG11201807960PA (en) | 2018-10-30 |
Family
ID=55586297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807960PA SG11201807960PA (en) | 2016-03-16 | 2016-03-16 | Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190105381A1 (ja) |
EP (2) | EP3770265B1 (ja) |
JP (1) | JP6724156B2 (ja) |
KR (1) | KR20180127402A (ja) |
CN (1) | CN108779473A (ja) |
CA (1) | CA3017541A1 (ja) |
DK (1) | DK3430147T3 (ja) |
ES (1) | ES2834656T3 (ja) |
IL (1) | IL261729B (ja) |
SG (1) | SG11201807960PA (ja) |
WO (1) | WO2017157437A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3429596T3 (da) | 2016-03-18 | 2022-10-24 | Immune Sensor Llc | Cykliske dinukleotide forbindelser og brugs metoder |
WO2019123414A1 (en) * | 2017-12-22 | 2019-06-27 | Straximm Llp | Engineered viruses expressing cyclic gmp-amp synthase |
CN113456810A (zh) * | 2020-03-30 | 2021-10-01 | 杭州星鳌生物科技有限公司 | 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用 |
WO2022223622A1 (en) | 2021-04-20 | 2022-10-27 | Institut Curie | Compositions and methods for use in immunotherapy |
EP4326769A1 (en) | 2021-04-20 | 2024-02-28 | Institut Curie | Compositions and methods for use in immunotherapy |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
AU2003242742B2 (en) * | 2002-06-20 | 2009-04-30 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
EP1447080A1 (en) * | 2003-02-13 | 2004-08-18 | Bestewil Holding B.V. | Method for producing virosome-like particles |
WO2005089777A1 (en) | 2004-03-15 | 2005-09-29 | Karaolis David K R | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
GB0426641D0 (en) * | 2004-12-03 | 2005-01-05 | Bioactive Protein Delivery The | Protein delivery system |
EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
DK2385107T3 (en) | 2010-05-03 | 2016-12-12 | Pasteur Institut | Lentiviral vector-based immunological compounds against malaria |
TWI526539B (zh) * | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
CN104507538B (zh) | 2012-06-08 | 2018-04-06 | 艾杜罗生物科技公司 | 癌症免疫疗法的组合物和方法 |
KR20150076244A (ko) | 2012-10-30 | 2015-07-06 | 레드박스 게엠베하 | 인간 시토메갈로바이러스 감염에 대한 재조합 입자 기재 백신 |
KR102255996B1 (ko) | 2012-12-19 | 2021-05-26 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 포유동물 시클릭 디-뉴클레오티드 신호 경로의 약학적 표적화 |
WO2014128568A2 (en) | 2013-02-25 | 2014-08-28 | Variation Biotechnologies, Inc. | Compositions and methods for treatment of hepatitis c |
EP3094342A4 (en) * | 2014-01-15 | 2017-12-27 | Nikolai Khodarev | Anti-tumor therapy |
-
2016
- 2016-03-16 DK DK16710729.1T patent/DK3430147T3/da active
- 2016-03-16 ES ES16710729T patent/ES2834656T3/es active Active
- 2016-03-16 KR KR1020187029376A patent/KR20180127402A/ko not_active Application Discontinuation
- 2016-03-16 CN CN201680083643.4A patent/CN108779473A/zh active Pending
- 2016-03-16 CA CA3017541A patent/CA3017541A1/en active Pending
- 2016-03-16 EP EP20193607.7A patent/EP3770265B1/en active Active
- 2016-03-16 EP EP16710729.1A patent/EP3430147B1/en active Active
- 2016-03-16 WO PCT/EP2016/055738 patent/WO2017157437A1/en active Application Filing
- 2016-03-16 SG SG11201807960PA patent/SG11201807960PA/en unknown
- 2016-03-16 US US16/084,991 patent/US20190105381A1/en not_active Abandoned
- 2016-03-16 JP JP2018548683A patent/JP6724156B2/ja active Active
-
2018
- 2018-09-12 IL IL261729A patent/IL261729B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL261729B (en) | 2022-02-01 |
EP3430147B1 (en) | 2020-09-09 |
KR20180127402A (ko) | 2018-11-28 |
US20190105381A1 (en) | 2019-04-11 |
JP6724156B2 (ja) | 2020-07-15 |
ES2834656T3 (es) | 2021-06-18 |
EP3770265A1 (en) | 2021-01-27 |
CA3017541A1 (en) | 2017-09-21 |
EP3430147A1 (en) | 2019-01-23 |
DK3430147T3 (da) | 2020-11-23 |
IL261729A (en) | 2018-10-31 |
EP3770265B1 (en) | 2023-10-11 |
EP3770265C0 (en) | 2023-10-11 |
CN108779473A (zh) | 2018-11-09 |
JP2019512249A (ja) | 2019-05-16 |
WO2017157437A1 (en) | 2017-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807960PA (en) | Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201806340YA (en) | Zika virus vaccine | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
SG11201811048UA (en) | Single-cell transcript sequencing | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201805204WA (en) | Nicotine particle capsule | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201809051YA (en) | Cell retention device and method | |
SG11201810793XA (en) | Pharmaceutical combinations | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201810670VA (en) | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |